TY - JOUR
T1 - Infection control in the intensive care unit
T2 - expert consensus statements for SARS-CoV-2 using a Delphi method
AU - Nasa, Prashant
AU - Azoulay, Elie
AU - Chakrabarti, Arunaloke
AU - Divatia, Jigeeshu V.
AU - Jain, Ravi
AU - Rodrigues, Camilla
AU - Rosenthal, Victor D.
AU - Alhazzani, Waleed
AU - Arabi, Yaseen M.
AU - Bakker, Jan
AU - Bassetti, Matteo
AU - De Waele, Jan
AU - Dimopoulos, George
AU - Du, Bin
AU - Einav, Sharon
AU - Evans, Laura
AU - Finfer, Simon
AU - Guérin, Claude
AU - Hammond, Naomi E.
AU - Jaber, Samir
AU - Kleinpell, Ruth M.
AU - Koh, Younsuck
AU - Kollef, Marin
AU - Levy, Mitchell M.
AU - Machado, Flavia R.
AU - Mancebo, Jordi
AU - Martin-Loeches, Ignacio
AU - Mer, Mervyn
AU - Niederman, Michael S.
AU - Pelosi, Paolo
AU - Perner, Anders
AU - Peter, John V.
AU - Phua, Jason
AU - Piquilloud, Lise
AU - Pletz, Mathias W.
AU - Rhodes, Andrew
AU - Schultz, Marcus J.
AU - Singer, Mervyn
AU - Timsit, Jéan François
AU - Venkatesh, Balasubramanian
AU - Vincent, Jean Louis
AU - Welte, Tobias
AU - Myatra, Sheila N.
N1 - Funding Information:
PN reports honoraria for lectures and other educational events from Tabuk Pharmaceuticals, and is a member of Edward Lifesciences Advisory Board Panel, outside of the submitted work. JVD reports personal fees (paid to institution) from Edwards India, outside the submitted work. MB reports honoraria for lectures and another educational event from Angelini, Bayer, bioMérieux, Cipla, Gilead Sciences, Menarini, Merck Sharp & Dohme (MSD), Pfizer, and Shionogi; grants from Pfizer and MSD, outside of the submitted work; and is on the advisory board of Cidara Therapeutics. JDW reports honoraria (paid to institution) for lectures and other educational events from MSD and Pfizer, outside of the submitted work. BD reports research grants from Ministry of Science and Technology, People's Republic of China (research grant 2020YFC0841300), and Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2020-I2M-2-005 and 2019-I2M-1-001), outside of the submitted work. LE reports consulting fees (paid to institution) for the National Emerging Special Pathogen Training and Education Centre, outside of the submitted work. SJ reports academic consultation fees from Drager, Fisher-Paykel, Medtronic, Baxter International, and Fresenius–Xenios; and honoraria for lectures and other educational events from Fisher-Paykel and Baxter, outside of the submitted work. MK reports honoraria from Merck and Pfizer for lectures and other educational events, outside of the submitted work. JM reports research grants (paid to institution) from Covidien (Medtronic) and Canadian Institutes of Health Research; personal consultation fees from Janssen Pharmaceuticals and Faron Pharmaceuticals; honoraria from Medtronic for lectures and other educational events; and a consulting agreement signed with Vyaire, outside of the submitted work. MSN reports personal consulting fees from Abbvie, outside of the submitted work. AP reports research grants from Novo Nordisk Foundation, Pfizer, and Fresenius Kabi, outside of the submitted work. MS reports research grants and advisory board fees from NewB; research grants from DSTL, Critical Pressure, and Apollo Therapeutics; speaking fees (paid to institution) from Amormed, advisory board fees from Biotest, GE, Baxter, Roche, and Bayer; and honoria from Shionogi, outside of the submitted work. BV reports research grants and honoraria for the guest lecture and other educational events from Baxter, outside of the submitted work. All other authors declare no competing interests.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/3
Y1 - 2022/3
N2 - During the current COVID-19 pandemic, health-care workers and uninfected patients in intensive care units (ICUs) are at risk of being infected with SARS-CoV-2 as a result of transmission from infected patients and health-care workers. In the absence of high-quality evidence on the transmission of SARS-CoV-2, clinical practice of infection control and prevention in ICUs varies widely. Using a Delphi process, international experts in intensive care, infectious diseases, and infection control developed consensus statements on infection control for SARS-CoV-2 in an ICU. Consensus was achieved for 31 (94%) of 33 statements, from which 25 clinical practice statements were issued. These statements include guidance on ICU design and engineering, health-care worker safety, visiting policy, personal protective equipment, patients and procedures, disinfection, and sterilisation. Consensus was not reached on optimal return to work criteria for health-care workers who were infected with SARS-CoV-2 or the acceptable disinfection strategy for heat-sensitive instruments used for airway management of patients with SARS-CoV-2 infection. Well designed studies are needed to assess the effects of these practice statements and address the remaining uncertainties.
AB - During the current COVID-19 pandemic, health-care workers and uninfected patients in intensive care units (ICUs) are at risk of being infected with SARS-CoV-2 as a result of transmission from infected patients and health-care workers. In the absence of high-quality evidence on the transmission of SARS-CoV-2, clinical practice of infection control and prevention in ICUs varies widely. Using a Delphi process, international experts in intensive care, infectious diseases, and infection control developed consensus statements on infection control for SARS-CoV-2 in an ICU. Consensus was achieved for 31 (94%) of 33 statements, from which 25 clinical practice statements were issued. These statements include guidance on ICU design and engineering, health-care worker safety, visiting policy, personal protective equipment, patients and procedures, disinfection, and sterilisation. Consensus was not reached on optimal return to work criteria for health-care workers who were infected with SARS-CoV-2 or the acceptable disinfection strategy for heat-sensitive instruments used for airway management of patients with SARS-CoV-2 infection. Well designed studies are needed to assess the effects of these practice statements and address the remaining uncertainties.
UR - http://www.scopus.com/inward/record.url?scp=85124997973&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(21)00626-5
DO - 10.1016/S1473-3099(21)00626-5
M3 - Review article
C2 - 34774188
AN - SCOPUS:85124997973
SN - 1473-3099
VL - 22
SP - e74-e87
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 3
ER -